Observational Study
Copyright ©The Author(s) 2022.
World J Hepatol. Jun 27, 2022; 14(6): 1226-1234
Published online Jun 27, 2022. doi: 10.4254/wjh.v14.i6.1226
Table 1 Demographics of subjects
Variables
ALL (n = 437)
Fatty liver (n = 110)
Non-fatty liver (n = 327)
P value
Gender (Male/Female)269/16880/30189/1380.005
Age (yr)74.0 ± 13.064.7 ± 13.077.1 ± 11.0< 0.001
Height (cm)159.4 ± 10.2163.2 ± 10.0158.2 ± 9.9< 0.001
Body weight (kg)61.3 ± 14.570.0 ± 16.658.5 ± 12.5< 0.001
BMI (kg/m2)24.0 ± 4.926.0 ± 4.723.3 ± 4.7< 0.001
HbA1c (%)7.0 ± 1.27.2 ± 1.26.9 ± 1.20.066
Blood glucose (mg/dl)164 ± 80170 ± 116161 ± 630.297
White blood cells (/μL)6618 ± 22997056 ± 16496470 ± 24630.021
Hemoglobin (g/dL)12.6 ± 2.414.2 ± 2.112.0 ± 2.2< 0.001
Platelets (104/μL)20.7 ± 7.020.4 ± 5.520.8 ± 7.40.615
Prothrombin time (%)89.6 ± 22.389.2 ± 23.689.7 ± 22.10.895
Albumin (g/dL)3.7 ± 0.73.9 ± 0.63.6 ± 0.6< 0.001
Total bilirubin (mg/dL)0.76 ± 0.500.86 ± 0.490.72 ± 0.490.015
ALP (U/L)266 ± 156247 ± 80272 ± 1760.182
AST (U/L)25.3 ± 22.829.0 ± 20.223.0 ± 23.40.014
ALT (U/L)23.5 ± 20.835.0 ± 27.419.0 ± 16.1< 0.001
GGT (U/L)46.2 ± 63.168.0 ± 74.438.0 ± 56.6< 0.001
Creatinine (mg/dL)1.71 ± 2.101.27 ± 1.581.85 ± 2.220.012
eGFR (mL/min)52.0 ± 29.258.9 ± 21.949.6 ± 30.90.004
Total cholesterol (mg/dL)181 ± 50193 ± 64177 ± 430.012
HDL cholesterol (mg/dL)53 ± 1750 ± 1554 ± 170.039
Triglyceride (mg/dL)160 ± 179228 ± 299134 ± 87< 0.001
LDL cholesterol (mg/dL)101 ± 36111 ± 4096 ± 330.001
FIB-4 index2.20 ± 1.561.84 ± 1.082.32 ± 1.670.005
Cirrhosis (%)8 (1.8)1 (0.9)7 (2.1)0.405
Hepatocellular carcinoma (%)7 (1.6)1 (0.9)6 (1.8)0.504
Cerebrovascular accident (%)45 (10)9 (8.2)36 (11)0.399
Cardiovasculart disease (%)137 (31)29 (26)108 (33)0.193
Dyslipidemia (%)205 (47)53 (48)152 (46)0.758
Hypertension (%)270 (62)57 (51)213 (65)0.013
Dialysis (%)45 (10)3 (2.7)42 (12)0.003